EGFR and frontotemporal dementia: Therefore, the proportion of anti‐EGFR therapy administered was likely to be comparable between cohorts B and C. In cohort C, FTD/TPI or regorafenib could be administered as late‐line treatment at the initiation of first‐line treatment; however, the proportion of FTD/TPI or regorafenib was low.